Psoriasis

A recent study examines systemic and phototherapy treatment utilization and drug survival in pediatric patients with psoriasis.

Arcutis Biotherapeutics, Inc has released data from its DERMIS-1 and DERMIS-2 Phase 3 pivotal studies demonstrating that the topical significantly reduced the burden and severity of itch.

Two poster presentations at the EADV 30th annual conference showed the efficacy of roflumilast foam for nonsteroidal treatment of psoriasis or seborrheic dermatitis.

Factors include extent of disease, the latest findings on agents’ efficacy, and even patient weight.

The new data examines delivery system efficacy of either 1 secukinumab 300-mg dose in an autoinjector vs 2 doses of secukinumab 150-mg 1 mL pre-filled syringes.

Even with patient hesitancy, treating PPP with gentian violet and chemical peels could help patients avoid biologics.

The FDA has approved halobetasol propionate foam, 0.05% (Lexette; Mayne Pharma), a potent topical corticosteroid, for the treatment of plaque psoriasis in adolescent patients.

The National Psoriasis Foundation has released new guidance statements after the Centers for Disease Control and Prevention provided new information on COVID-19 vaccine boosters for immunocompromised patients.

A recently published study compared cognition, MRI-markers, and dementia risk in patients diagnosed with psoriasis vs those without psoriasis.

Lack of specific phenotypes complicates verification.

According to a study in Annals of Dermatology and Venerology, pediatric patients with psoriasis in France frequently missed dermatologic consultations.

The FDA is now requiring black box warning for certain JAK inhibitors used to treat arthritis. This news comes amid delay in FDA approval for multiple JAK inhibitors for the treatment of inflammatory skin conditions.

Some systemic medications may have increased risk for patients during the COVID-19 era, according to a recent Pediatric Dermatology Research Alliance (PeDRA) statement.

Theresa Vavra, PharmD, BCPS, provides studies for some of the most commonly used supplements by patients with psoriasis.

Whitney Linsenmeyer, PhD, RD, LD, provides 3 dietary considerations for patients with psoriasis.

COVID-19’s lingering impact brings new considerations for treatment regimens for pediatric patients with psoriasis.

Holistic options for disease management show improvement in mild psoriasis.

UCB announced the European Commission have granted marketing authorization for bimekizumab for the treatment of moderate to severe plaque psoriasis.

Jennifer Powers, MD, associate professor of dermatology at the University of Iowa, talks her recent research investigating how diet and supplements affect patients with mild psoriasis.

Due to the multimorbid nature of the disease, clinicians must screen, monitor, and aggressively treat the associated comorbidities.

More research is needed to understand the pathogenesis underlying this association.

The International Psoriasis Council (IPC)’s new binary classification system aims to streamline access to systemic treatments for patients who previously were likely undertreated.

UCB announced that more than 90% of patients treated with bimekizumab have maintained IGA 1/0 results in their long-term BE BRIGHT trial.

The FDA has accepted the New Drug Application (NDA) for tapinarof as a treatment for plaque psoriasis in adults and set the PDUFA target action date to Q2 2022.

Mark Lebwohl, MD, explains the recent delay in approval of JAK inhibitors by the FDA, how it is affecting the inflammatory skin disease community, and if physicians should be concerned.

In this video interview, Jerry Bagel, MD, MS, discusses improvement in quality of life for pediatric psoriasis patients and current and emerging treatments.

As COVID-19 eases, the FDA is breaking through its backlog and clinical trials are moving forward, opening the way for a new wave of treatments.

Amgen and the International Federation of Psoriasis Associations have announced their efforts to combat the challenges of psoriasis.

BFI-751, Biofactura’s biosimilar drug to ustekinumab will be investigated for the first time on human patients.

Camp Wonder, a camp that supports kids with skin disease and is sponsored by Galderma, is celebrating their 20th year of operations this week.